JP2015512412A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512412A5 JP2015512412A5 JP2015503545A JP2015503545A JP2015512412A5 JP 2015512412 A5 JP2015512412 A5 JP 2015512412A5 JP 2015503545 A JP2015503545 A JP 2015503545A JP 2015503545 A JP2015503545 A JP 2015503545A JP 2015512412 A5 JP2015512412 A5 JP 2015512412A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- composition
- trail
- binding
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 24
- 230000027455 binding Effects 0.000 claims 11
- 108700012411 TNFSF10 Proteins 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 9
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 claims 5
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 claims 5
- 230000006907 apoptotic process Effects 0.000 claims 5
- 230000009870 specific binding Effects 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 2
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261616929P | 2012-03-28 | 2012-03-28 | |
| US61/616,929 | 2012-03-28 | ||
| PCT/US2013/034163 WO2013148877A1 (en) | 2012-03-28 | 2013-03-27 | Dr5 receptor agonist combinations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015512412A JP2015512412A (ja) | 2015-04-27 |
| JP2015512412A5 true JP2015512412A5 (https=) | 2016-04-28 |
| JP6219923B2 JP6219923B2 (ja) | 2017-10-25 |
Family
ID=48087754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503545A Expired - Fee Related JP6219923B2 (ja) | 2012-03-28 | 2013-03-27 | Ｄｒ５受容体アゴニストの組み合わせ |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20150056204A1 (https=) |
| EP (1) | EP2831116A1 (https=) |
| JP (1) | JP6219923B2 (https=) |
| AU (1) | AU2013239682B2 (https=) |
| CA (1) | CA2867631C (https=) |
| HK (1) | HK1206760A1 (https=) |
| MX (1) | MX350202B (https=) |
| WO (1) | WO2013148877A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11299528B2 (en) | 2014-03-11 | 2022-04-12 | D&D Pharmatech Inc. | Long acting TRAIL receptor agonists for treatment of autoimmune diseases |
| EP3048116A1 (en) * | 2015-01-23 | 2016-07-27 | International-Drug-Development-Biotech | Anti-dr5 antibodies with enhanced apoptosis potency |
| SG11201706024YA (en) | 2015-01-26 | 2017-08-30 | Macrogenics Inc | Multivalent molecules comprising dr5-binding domains |
| EP3337505A4 (en) * | 2015-08-19 | 2019-02-27 | Sinotau Pharmaceuticals Group | TRAIL-RECEPTOR BINDING AGENTS AND USES THEREOF |
| WO2017106627A1 (en) | 2015-12-17 | 2017-06-22 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
| KR102508650B1 (ko) | 2016-04-07 | 2023-03-13 | 더 존스 홉킨스 유니버시티 | 사멸 수용체 작용제로써 췌장암 및 통증을 치료하기 위한 조성물 및 방법 |
| KR101926834B1 (ko) * | 2017-03-21 | 2018-12-07 | 동아에스티 주식회사 | 항-dr5 항체 및 그의 용도 |
| EP3672634A1 (en) * | 2017-08-24 | 2020-07-01 | Invenra, Inc. | Multivalent receptor-clustering agonist antibody constructs |
| WO2022154664A1 (en) * | 2021-01-15 | 2022-07-21 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer |
| WO2025098480A1 (zh) * | 2023-11-10 | 2025-05-15 | 信达生物制药(苏州)有限公司 | 抗dr5和ceacam5的双特异性抗体及其用途 |
| WO2025193146A1 (en) * | 2024-03-13 | 2025-09-18 | Berg Thoren Fredrik | Trail receptor binding molecules |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| CA2118130A1 (en) | 1992-04-14 | 1993-10-28 | Jean M. J. Frechet | Dendritic based macromolecules and method of production |
| US6284236B1 (en) | 1995-06-29 | 2001-09-04 | Immunex Corporation | Cytokine that induces apoptosis |
| US6998116B1 (en) | 1996-01-09 | 2006-02-14 | Genentech, Inc. | Apo-2 ligand |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US6342363B1 (en) | 1997-01-28 | 2002-01-29 | Human Genome Sciences, Inc. | Death domain containing receptor 4 nucleic acids and methods |
| US7528239B1 (en) | 1997-02-13 | 2009-05-05 | Immunex Corporation | Receptor that binds trail |
| US6872568B1 (en) * | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
| US6342369B1 (en) | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
| US6100082A (en) | 1997-09-23 | 2000-08-08 | Hassanein; Waleed H. | Perfusion apparatus and method including chemical compositions for maintaining an organ |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| WO2000066156A1 (en) * | 1999-05-04 | 2000-11-09 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
| US7279160B2 (en) * | 2000-05-02 | 2007-10-09 | The Uab Research Foundation | Combinations of DR5 antibodies and other therapeutic agents |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| CA2489348A1 (en) | 2002-06-24 | 2003-12-31 | Genentech, Inc. | Apo-2 ligand/trail variants and uses thereof |
| GB0328261D0 (en) | 2003-12-05 | 2004-01-07 | Univ Groningen | Improved cytokine design |
| US8029783B2 (en) * | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
| WO2006094269A2 (en) | 2005-03-03 | 2006-09-08 | Covx Technologies Ireland Limited | Anti-angiogenic compounds |
| PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| EP2089425B1 (en) | 2006-11-10 | 2011-08-17 | CovX Technologies Ireland Limited | Anti-angiogenic compounds |
| GB0704651D0 (en) * | 2007-03-09 | 2007-04-18 | Ucl Business Plc | Composition |
| US9120855B2 (en) * | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
| AU2011252841B2 (en) * | 2010-05-14 | 2014-04-03 | Amgen Inc. | Enhanced death receptor agonists |
-
2013
- 2013-03-27 EP EP13715858.0A patent/EP2831116A1/en not_active Withdrawn
- 2013-03-27 AU AU2013239682A patent/AU2013239682B2/en not_active Ceased
- 2013-03-27 JP JP2015503545A patent/JP6219923B2/ja not_active Expired - Fee Related
- 2013-03-27 WO PCT/US2013/034163 patent/WO2013148877A1/en not_active Ceased
- 2013-03-27 US US14/388,762 patent/US20150056204A1/en not_active Abandoned
- 2013-03-27 HK HK15107435.1A patent/HK1206760A1/xx unknown
- 2013-03-27 CA CA2867631A patent/CA2867631C/en not_active Expired - Fee Related
- 2013-03-27 MX MX2014011540A patent/MX350202B/es active IP Right Grant
-
2018
- 2018-10-31 US US16/176,343 patent/US20190284290A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015512412A5 (https=) | ||
| Harbeck et al. | HER2 dimerization inhibitor pertuzumab-mode of action and clinical data in breast cancer | |
| HRP20211346T1 (hr) | Kombinirani pripravci za liječenje raka | |
| CA2886433C (en) | Human monoclonal anti-pd-l1 antibodies and methods of use | |
| PH12019502484A1 (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| JP2020503891A5 (https=) | ||
| TN2019000294A1 (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| JP2012046518A5 (https=) | ||
| JP2016041733A5 (https=) | ||
| JP2020527144A5 (https=) | ||
| JP2015506961A5 (https=) | ||
| JP2018516966A5 (https=) | ||
| JP2016539096A5 (https=) | ||
| JP2016528195A5 (https=) | ||
| HRP20211710T1 (hr) | Konjugacija specifična za mjesto spajanja lijekova za povezivanje s protutijelima i konjugati protutijela u lijeku koji nastaje kao rezultat | |
| JP2015534577A5 (https=) | ||
| MX2022005404A (es) | Compuestos de fijación a il-2r e il-7r dual. | |
| EP2579895A4 (en) | ANTI-VEGF ANTIBODIES AND USES THEREOF | |
| NZ601943A (en) | Antibodies against cxcr4 | |
| JP2010500370A5 (https=) | ||
| JP2017518260A5 (https=) | ||
| JP2013523843A5 (https=) | ||
| MX2014011540A (es) | Combinaciones de agonistas de receptores de muerte 5 (dr5). | |
| WO2017177217A3 (en) | Chimeric receptors and uses thereof in immune therapy | |
| EA201992513A1 (ru) | Способ лечения рака груди |